Q1 2025 Earnings Call Transcript May 14, 2025 Allurion Technologies Inc. beats earnings expectations. Reported EPS is $0.43, expectations were $-1.53. Operator: Hello, everyone, and welcome to ...

Q1 2025 Earnings Conference Call May 14, 2025 8:30 AM ETCompany ParticipantsTara Brady - Interim CFOShantanu Gaur ...

Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion” or the “Company”), a pioneer in metabolically healthy weight loss, today announced its financial results for the first quarter and ...

Discover Allurion Technologies' Q1 2025 earnings highlights, featuring a revamped B2B2C strategy, FDA progress, improved margins, and future growth plans.

The Global Weight Management Market is expected to witness a growth rate of 9-10% by 2029. The market has experienced ...

Allurion Technologies, Inc. (NYSE: ALUR) ("Allurion" or the "Company"), a pioneer in metabolically healthy weight loss, today announced its financial results for the first quarter and provided a ...

GLP-1s used in combination with the Virtual Care Suite led to an average gain in lean body mass of 6.1%, the company said. Data was also presented showing that Allurion Balloon used in combination ...

“We believe there is a massive and largely untapped opportunity for the Allurion Program to be not just an alternative to GLP-1 medications, but complementary to them,” continued Dr. Gaur.

Allurion Technologies, Inc. (ALUR) delivered earnings and revenue surprises of 128.10% and 2.11%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the ...

Allurion Technologies Inc (ALUR) reports significant operational improvements and strategic progress despite a dip in revenue due to temporary market suspensions.